Crinetics Pharmaceuticals, Inc. (CRNX)
NASDAQ: CRNX · Real-Time Price · USD
84.95
0.00 (0.00%)
Sep 1, 2026, 4:00 PM EDT - Market closed
Crinetics Pharmaceuticals Revenue
Crinetics Pharmaceuticals had revenue of $25.12M in the quarter ending June 30, 2026, with 2,336.28% growth. This brings the company's revenue in the last twelve months to $42.16M, up 3,957.36% year-over-year. In the year 2025, Crinetics Pharmaceuticals had annual revenue of $7.70M with 640.71% growth.
Revenue (ttm)
$42.16M
Revenue Growth
+3,957.36%
P/S Ratio
213.74
Revenue / Employee
$70,970
Employees
594
Market Cap
9.01B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.70M | 6.66M | 640.71% |
| Dec 31, 2024 | 1.04M | -2.97M | -74.11% |
| Dec 31, 2023 | 4.01M | -724.00K | -15.28% |
| Dec 31, 2022 | 4.74M | 3.66M | 339.42% |
| Dec 31, 2021 | 1.08M | 1.01M | 1,418.31% |
| Dec 31, 2020 | 71.00K | -1.12M | -94.05% |
| Dec 31, 2019 | 1.19M | -1.24M | -50.86% |
| Dec 31, 2018 | 2.43M | 383.00K | 18.73% |
| Dec 31, 2017 | 2.05M | 1.46M | 247.20% |
| Dec 31, 2016 | 589.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Ionis Pharmaceuticals | 874.09M |
| TG Therapeutics | 799.54M |
| Protagonist Therapeutics | 281.99M |
| ImmunityBio | 165.79M |
| Kymera Therapeutics | 105.00M |
| Cytokinetics | 67.67M |
| Praxis Precision Medicines | 7.46M |
CRNX News
- 1 day ago - Vertex Pharmaceuticals completes acquisition of Crinetics Pharmaceuticals - TheFly
- 1 day ago - Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team - Business Wire
- 4 weeks ago - Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update - GlobeNewsWire
- 4 weeks ago - Crinetics Pharmaceuticals Earnings release: Q2 2026 - Filings
- 4 weeks ago - Crinetics Pharmaceuticals Quarterly report: Q2 2026 - Filings
- 4 weeks ago - Crinetics Pharmaceuticals Proxy statement: Proxy filing - Filings
- 5 weeks ago - Crinetics downgraded to Neutral from Buy at UBS - TheFly
- 6 weeks ago - BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: TriCo Bancshares (Nasdaq – TCBK), Twin Vee PowerCats Co. (Nasdaq -VEEE), Crinetics Pharmaceuticals, Inc. (Nasdaq – CRNX), Element Solutions Inc. (NYSE – ESI) - GlobeNewsWire